Module 4.2.1 (Pharmacology of Drugs for Multiple Sclerosis) Flashcards

1
Q

What is MS?

A

MS is an inflammatorymediated demyelinating disease of the CNS

> Inflammatory lesions are characterised by high infiltration of

Immune cellular and soluble mediators: T & B cells „ Macrophages „ Microglia

A broad range of: Cytokines „ Chemokines „ Antibodies „ Complement „ Toxic substances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Several disease-modifying therapies with different mechanisms of action are available for MS. These have immunosuppressive & immunomodulatory effects that target:

A) Lymphocyte number

B) Lymphocyte proliferation

C) Lymphocyte trafficking

D) Cyotkine production

A

A)

  • Alemtuzumab
  • Ocrelizumab
  • Cladribine

B)

  • Teriflunomide

C)

  • Fingolimod
  • Natalizumab

D)

  • Interferon beta
  • Glatiramer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Summary of drugs and the type of MS used for

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is included in the types of interferon? MOA?

A
  • Interferon beta-1a
  • Interferon beta-1b
  • Peginterferon beta-1a

MOA

  • Exact mechanism unknown - thought to act through immunoregulatory actions
  • Interferon beta reduces cytokine release and enhances suppressor T cell activity, inhibits lymphocyte trafficking into CNS & also reduces the amount of interferon-gamma secreted by activated lymphocytes.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

AE (CIR) and precautions of interferon

A

Common

  • Injection site reactions
  • Flu-like Sx
  • Headache
  • Interferon beta neutralising antibodies

> Incidence lower with peginterferon beta

Infrequent

  • Hypertension, seizures

Rare

  • Palpitations, HF, cardiomyopathy
  • Thrombocytopenia
  • Hepatotoxicity

Precautions

> Cardiac disease eg heart failure – may worsen

> Seizure disorder – may worsen or reoccur

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the MOA of Alemtuzumab?

A
  • Recombinant humanised monoclonal antibody
  • Binds to CD52 surface protein on T and B lymphocytes, resulting in their depletion with subsequent repopulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

AE (CI) and precuations of Alemtuzumab

A

Common „

  • Infusion related reactions „
  • Autoimmune disorders „
  • Infection „
  • Lymphopenia

Infrequent

  • Pneumonitis

Precautions

Infection –> CI in HIV infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

MOA of dimethyl fumarate?

A
  • Is a derivative of fumaric acid
  • Thought to activate the nuclear factor (erythroid derived 2)-like 2 (Nrf2) transcriptional pathway

> Activation of this pathway results in antiinflammatory and antioxidant actions

  • Taken orally bd
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

AE (CR) and precuations of dimethyl fumarate

A

Common

  • Flushing „
  • GI SE eg N, V, D, abdominal pain „
  • Leucopenia „
  • Lymphopenia

Rare

  • PML = viral disease of white matter of the brain

Precautions

  • Infection
  • Persistent severe lymphopenia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the MOA of fampridine?

A

potassium channel blocker

  • Thought to increase conduction in demyelinated nerves by inhibiting potassium channels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the indications of fampridine?

A

Symptomatic improvement of walking in adults with MS (in those with walking disability

  • If no response within 8 weeks - stop

> oral bd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

AE (CR) of fampridine and precautions

A

Common

  • UTI
  • Insomnia
  • Dizziness
  • Headache
  • Anxiety

Rare

  • Seizure

Precuations

  • Epilepsy, Hx of seizures = CI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MOA of fingolimod?

A

Is a sphingosine 1-phosphate receptor modulator

  • Fingolimod traps naive memory T cells and effector memory T cells in lymph nodes
  • Prevents cells from entering the bloodstream and therefore crossing the blood-brain barrier thus reducing inflammation and demyelination

> dose od

> eliminated by metabolism –> most of the metabolites are excreted in the urine (t1/2 = 6–9 days so it takes several weeks to reach steady state)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

AE (CIR), precautions and drug interactions for fingolimod?

A

Common

  • Bradycardia
  • First-degree AV block
  • Infection eg lower RTI, influenza
  • Basal cell carcinoma

Infrequent

  • Melanoma
  • Second-degree AV block

Rare

  • Opportunistic CNS infections including cryptococcal meningitis & PML

Precautions

  • Cerebrovascular or cardiovascular disease – use not recommended
  • Diabetes - ↑ risk of macular oedema

Drug Interactions

  • CYP3A4 may metabolise fingolimod
  • Combining it with CYP3A4 inhibitors eg clarithromycin may increase its conc & the risk for adverse effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MOA of glatiramer?

A

Is a synthetic protein that mimics the structure of myelin basic protein

  • Which is a component of the myelin covering nerve fibre.

> Blocks myelin damaging T cells by acting as a myelin decoy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

AE (CR), precautions of Glatriamer

A

Common

Injection site reactions

Immediate post-injection rx

Rare

Anaphylaxis

  • Antibodies

Precuations

  • Asthma, Hx of severe anaphylaxis – may ↑ risk of allergic rx

Dosing = SC once daily

17
Q

MOA of Natalizumab

A

Is a recombinant humanised monoclonal antibody to alpha-4-integrins

  • Exact mode not known but thought to inhibit WBC migration from blood into CNS ∴ ↓ inflammation & demyelination

> alpha 4 integrin antagonist

18
Q

AE (CR), precautions for natalizumab

A

Common

  • Infection „
  • Anti-natalizumab antibodies „
  • Hypersensitivity & infusion related rxs

Rare

  • PML – monitor pt and hepatoxicity

Antibodies may develop in some patients reducing efficacy of natalizumab

Precautions

  • Immunocompromised = CI

Dose: IV infusion every 4 weeks

19
Q

MOA of Ocrelizumab?

A

Is a recombinant humanised monoclonal antibody directed against CD20 antigen expressed by B cells –> rapid depletion

  • Mechanism of action in MS not fully understood
20
Q

AE (C), precuations of (ocrelizumab)

A

Common

  • Hypersensitivity & infusion related rxs
  • Infection
  • Neutropenia

Precuations

  • Malignancy
21
Q

MOA of Teriflunomide

A

Inhibits pyrimidine synthesis in leucocytes by inhibiting activity of dihydroorotate dehydrogenase

  • May reduce numbers of activated lymphocytes in the CNS.
22
Q

AE (CRI), precautions for teriflunomide

A

Common

  • Infection
  • Increased aminotransferase concs

Infrequent

  • Lymphopenia

Rare

  • Hypersensitivity rxs
  • SJS
  • Hepatitis

Precautions

  • CI in severe liver impairment
  • Severe immnodeficiency = CI

> Is an active metabolite of leflunomide (rheumatoid arthritis drug) –> contraindicated